indazoles has been researched along with Carcinoma, Medullary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bible, KC; Bieber, C; Burton, JK; Cher Goh, B; Erlichman, C; Fatourechi, V; Flynn, PJ; Harris, P; Hay, I; Isham, CR; Karlin, N; Maples, WJ; McIver, B; Menefee, ME; Molina, JR; Morris, JC; Rubin, J; Sideras, K; Smallridge, RC; Suman, VJ; Traynor, AM; Webster, KP | 1 |
| Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
1 review(s) available for indazoles and Carcinoma, Medullary
| Article | Year |
|---|---|
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
1 trial(s) available for indazoles and Carcinoma, Medullary
| Article | Year |
|---|---|
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Medullary; Disease Progression; Female; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2014 |